Five-year Treatment Outcomes In The Ahmed Baerveldt Comparison Study

dc.creatorBudenz
dc.creatorDonald L.; Barton
dc.creatorKeith; Gedde
dc.creatorSteven J.; Feuer
dc.creatorWilliam J.; Schiffman
dc.creatorJoyce; Costa
dc.creatorVital P.; Godfrey
dc.creatorDavid G.; Buys
dc.creatorYvonne M.
dc.date2015-FEB
dc.date2016-06-07T13:36:26Z
dc.date2016-06-07T13:36:26Z
dc.date.accessioned2018-03-29T01:51:46Z
dc.date.available2018-03-29T01:51:46Z
dc.identifier
dc.identifierFive-year Treatment Outcomes In The Ahmed Baerveldt Comparison Study. Elsevier Science Inc, v. 122, p. 308-316 FEB-2015.
dc.identifier0161-6420
dc.identifierWOS:000348290000023
dc.identifier10.1016/j.ophtha.2014.08.043
dc.identifierhttp://www.sciencedirect.com/science/article/pii/S0161642014008124
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/244304
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1308002
dc.descriptionPurpose: To compare the 5-year outcomes of the Ahmed FP7 Glaucoma Valve (AGV) (New World Medical, Cucamonga, CA) and the Baerveldt 101-350 Glaucoma Implant (BGI) (Abbott Medical Optics, Abbott Park, IL) for the treatment of refractory glaucoma. Design: Multicenter, randomized, controlled clinical trial. Participants: A total of 276 patients, including 143 in the AGV group and 133 in the BGI group. Methods: Patients aged 18 to 85 years with previous intraocular surgery or refractory glaucoma and intraocular pressure (IOP) of >= 18 mmHg in whom glaucoma drainage implant (GDI) surgery was planned were randomized to implantation of an AGV or a BGI. Main Outcome Measures: Surgical failure, IOP, visual acuity (VA), use of glaucoma medications, and complications. Results: At 5 years, IOP (mean +/- standard deviation [SD]) was 14.7 +/- 4.4 mmHg in the AGV group and 12.7 +/- 4.5 mmHg in the BGI group (P = 0.015). The number of glaucoma medications in use at 5 years (mean +/- SD) was 2.2 +/- 1.4 in the AGV group and 1.8 +/- 1.5 in the BGI group (P = 0.28). The cumulative probability of failure during 5 years of follow-up was 44.7% in the AGV group and 39.4% in the BGI group (P = 0.65). The number of subjects failing because of inadequately controlled IOP or reoperation for glaucoma was 46 in the AGV group (80% of AGV failures) and 25 in the BGI group (53% of BGI failures; P = 0.003). Eleven eyes in the AGV group (20% of AGV failures) experienced persistent hypotony, explantation of implant, or loss of light perception compared with 22 eyes (47% of failures) in the BGI group. Change in logarithm of the minimum angle of resolution VA (mean +/- SD) at 5 years was 0.42 +/- 0.99 in the AGV group and 0.43 +/- 0.84 in the BGI group (P = 0.97). Conclusions: Similar rates of surgical success were observed with both implants at 5 years. The BGI produced greater IOP reduction and a lower rate of glaucoma reoperation than the AGV, but the BGI was associated with twice as many failures because of safety issues. (C) 2015 by the American Academy of Ophthalmology.
dc.description122
dc.description2
dc.description
dc.description308
dc.description316
dc.descriptionNational Institutes of Health [P30 EY014801]
dc.descriptionResearch to Prevent Blindness
dc.description
dc.description
dc.description
dc.languageen
dc.publisherELSEVIER SCIENCE INC
dc.publisher
dc.publisherNEW YORK
dc.relationOPHTHALMOLOGY
dc.rightsembargo
dc.sourceWOS
dc.subjectGlaucoma Drainage Implants
dc.subjectRandomized Clinical-trial
dc.subjectRefractory Glaucoma
dc.subjectAqueous Shunts
dc.subjectSingle-surgeon
dc.subjectFollow-up
dc.subjectSociety
dc.subjectValve
dc.titleFive-year Treatment Outcomes In The Ahmed Baerveldt Comparison Study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución